Slide 1: Defining the Future of Life-Saving Diagnostics at the Point of Care
Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | March 23, 2022 © 2022 Hyperfine, Inc.
Slide 2: Forward Looking Statements
© 2022 Hyperfine, Inc. | Confidential and Proprietary Forward Looking Statements This presentation includes forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Any
Slide 3: Mission: transform healthcare with life-saving diagnostics at the bedside
Today, brain diagnostics are single point-in-time and delay the time from door to discharge. Our mission is to transform healthcare by creating access to life-saving diagnostics and actionable data at the patient bedside. © 2022 Hyperfine, Inc. | Confidential and Proprietary
Slide 4: The Hyperfine Ecosystem
The Hyperfine Ecosystem A full ecosystem solution: Hardware, software, consumables and applications powered by artificial intelligence Democratizing Imaging, Sensing, and Guided Intervention to cover the care continuum Sensing (in development) Imaging (FDA cleared) Intervention (exploratory) © 2022
Slide 5: Imaging, Sensing, and Guided Intervention are Large Markets Poised for Disruption
Imaging, Sensing, and Guided Intervention are Large Markets Poised for Disruption $23B $22B $28B Imaging: Commercially Available Hospitals, Outpatient >100,000 Potential installation targets Sensing: In Development ICUs, Expanded Hospital, Surgical Centers, Outpatient, At-home ~4M Potential unit sal
Slide 6: We are Transforming Medical Imaging with Swoop MRI
We are Transforming Medical Imaging with Swoop® MRI 1.0 1980 MRI 2.0 1990 MRI 3.0 FDA Cleared 2020 © 2022 Hyperfine, Inc. | Confidential and Proprietary 6
Slide 7: Swoop is the Next Generation of MRI
Swoop® is the Next Generation of MRI Installed base of 70 units* as of year-end 2021 Clinical Applications including: Neuro ICU Follow-Up and Post-Operative Hydrocephalus and Pediatrics Stroke Portable low-field MRI Patent protected noise cancellation system enables clinical-grade images FDA Cleared
Slide 8: Swoop Brings MRI to the Patient
Swoop® Brings MRI to the Patient Acute Care Settings Swoop is designed to enable rapid diagnoses and treatment for patients regardless of income, resources, or location Produces high-quality images at low magnetic field strength, allowing clinicians to quickly scan, diagnose, and treat patients Whee
Slide 9: Clinical & Workflow Benefits
Clinical & Workflow Benefits
Slide 10: Numerous challenges with conventional MRI
Numerous challenges with conventional MRI : Adverse events occur in 22-46% of cases during transport High-cost limits accessibility Complex site requirements and upgrades Scheduling delays lead to longer length of stay Consumption of valuable personnel resources Risk of adverse events during transpo
Slide 11: Hyperfine Workflow Benefits
Hyperfine Workflow Benefits MRI ordered Patient preparation Intra-hospital transfer to MRI MRI examination Intra-hospital transfer to unit Post MRI examination Traditional MRI workflow (25.8 hours) MRI ordered MRI examination Post MRI examination Hyperfine workflow (90 mins, 94% reduction in total w
Slide 12: Swoop Clinical Use Cases Today
Intensive Care Unit Acute Mental Status Change Ataxia Cerebral Edema Cerebrovascular Disease Cranial Neuropathy Extra Ventricular Drain Placement Follow-up Intracranial Hemorrhage Follow-up Ischemic Stroke Follow-up Hematoma Stroke Tumor Pre- and Post-Op Emergency Department Blurred Vision Cranial N
Slide 13: Clinical Validation of Hyperfine
Clinical Validation of Hyperfine Game changer is a good way to put it […] being able to do the level of sophisticated imaging in an ICU that MRI can provide.’’ Dr. Fady Charbel, MD, FAANS, FACS Hyperfine provides me with an opportunity to acquire the information, to interpret the information, and to
Slide 14: Use Case: Neuro-ICU
Use Case: Neuro-ICU HYPERFINE
Slide 15: Patient Delays to Transfer in the ICU Create Major Unnecessary Costs
Patient Delays to Transfer in the ICU Creates Major Unnecessary Costs for Hospitals, is “Common and Costly” Estimated $300/hr for delays, >$22,000/week for hospital (>$1M/year) for large academic center Imaging capabilities of MRI, CT and Ultrasound should be available 24/7/365 at all facilities. In
Slide 16: Current ICU Imaging Workflow with Conventional MRI
Current ICU Imaging Workflow with Conventional MRI Patient preparation Intra-hospital transfer to MRI MRI examination Intra-hospital transfer to unit Post MRI examination Traditional MRI workflow can lead to prolonged delays in patient care and higher resources consumption MRI availability © 2022 Hype
Slide 17: Improved ICU Imaging Workflow with Swoop
MRI Ordered MRI Examination Post MRI Examination Portable MRI workflow enables timely care for earlier discharge by bringing brain imaging to the patient’s bedside Faster Transfer from ICU Faster Treatment Continue Monitoring with… Improved ICU Imaging Workflow with Swoop © 2022 Hyperfine, Inc. | Conf
Slide 18: Word from the Clinician
Using the scanner in the ICU is an important use case. What Swoop can offer versus a conventional MRI is the flexibility and the usefulness of having it right there. It favors time in a situation when you need something acute. Dr. Jennifer Moliterno-Gunel, Neurosurgeon Yale University School of Medic
Slide 19: Swoop's Potential Benefits in the ICU
Swoop’s Potential Benefits in the ICU Reduced adverse events associated with patient transport Adverse events occur in up to 46% of transported patients. Reduced costs associated with length of stay Shortening time to diagnosis, avoiding interruptions in care, and preventing adverse events Optimized
Slide 20: Use Case: Hydrocephalus
Use Case: Hydrocephalus HYPERFINE
Slide 21: Pediatric Hydrocephalus Management is a Huge Problem
Pediatric Hydrocephalus Management is a Huge Problem ~400,000 hospital days, $2B in hospital charges in the US Children with hydrocephalus need life-long monitoring and use a disproportionate number of hospital days and resources.1, 2 Any symptoms cause trips to hospital for a shunt check to ensure
Slide 22: Personal Story from the Hydrocephalus Association
Personal Story from the Hydrocephalus Association Received so many CT scans that we’re waiting on a cancer diagnosis. No radiation... Swoop is a parent’s dream. © 2022 Hyperfine, Inc. | Confidential and Proprietary
Slide 23: Hydrocephalus Workflow Improvement with Swoop
Hydrocephalus Workflow Improvement with Swoop® Traditional workflow results in delayed diagnosis and potential radiation exposure Hyperfine allows children to be imaged sooner, next to their loved ones, without radiation Patient preparation Transfer to imaging Fast MRI or CT Transfer to unit Diagnosi
Slide 24: Hydrocephalus: Swoop's Potential from Early Cases
Hydrocephalus: Swoop’s Potential from Early Cases Hyperfine is an excellent addition to the neurosurgery clinic for screening of hydrocephalus patients. The convenience for the patient, reduced scan time, and cost of the machine make this a device that should be considered for any neurosurgery clini
Slide 25: Use Case: Stroke
Use Case: Stroke HYPERFINE
Slide 26: Hyperfine Provides Compelling Platform for Stroke Diagnosis
Hyperfine Provides Compelling Platform for Stroke Diagnosis 15 million people worldwide suffer a stroke annually Stroke is the 2nd leading cause of death globally 87% strokes are ischemic strokes MRI scans are better at detecting ischemic stroke damage compared to CT scans MRI use for stroke has bee
Slide 27: Stroke Diagnosis Confirmed
Stroke Diagnosis Confirmed 62-year-old male Presented with new left sided weakness and tremor © 2022 Hyperfine, Inc. | Confidential and Proprietary 27
Slide 28: Clinical Settings Growth
Clinical Settings Growth ~1000 Neonatal ICUs ~1250 Operating Rooms and Angio Suites ~115 Neuro ICU’s Today’s use cases provide a sizeable opportunity and platform for growth. © 2022 Hyperfine, Inc. | Confidential and Proprietary Near-Term Focus Over Time ~340 Pediatric Clinics 28 ~220 Childrens’ Hos
Slide 29: Pipeline Opportunities
Pipeline Opportunities HYPERFINE
Slide 30: Innovative R&D Engine Designed to Expand Product Roadmap
Innovative R&D Engine Designed to Expand Product Roadmap Neuro-ICU Hydrocephalus Extremities Intra and Post Operative Expanded Addressable Market Improved usability Automated Stroke Detection Lower cost of goods Existing applications V1 Potential future applications V2 C-spine Potential benefits: ©
Slide 31: Developing a Non-Invasive Brain Vital Sensor
*The first medical device is being developed to aid in the diagnosis and management of brain disorders through the development of novel acoustic sensing techniques and innovative algorithms for measuring key metrics of brain health. Developing a Non-Invasive Brain Vital Sensor Breakthrough technolog
Slide 32: Brain-Sensing Clinical Opportunities
Brain-Sensing Clinical Opportunities Intensive Care Unit Emergency Department Operating Room Outpatient & At Home Hydrocephalus Vasospasm Stroke Cerebral edema Traumatic Brain Injury Subarachnoid hemorrhage Suspected seizures Acute liver failure Altered mental status Brain tumors Sepsis - Intraopera
Slide 33: Financial Profile
Financial Profile HYPERFINE
Slide 34: 2021 Financial Results & Total Installed Units
2021 Financial Results & Total Installed Units $1.496 million in 2021 total revenue Total sales increased by $1.2 million, or >400%, for the year ended December 31, 2021 compared to the year ended December 31, 2020. © 2022 Hyperfine, Inc. | Confidential and Proprietary TOTAL INSTALLED UNITS 2020 202
Slide 35: 2022 Financial Guidance
2022 Financial Guidance $10.0-$12.0 million in total revenue for full year 2022 50-60 commercial system installations in full year 2022 *2022 bar chart values reflect fiscal year financial guidance, not reported results
Slide 36: 2021 & 2022: Major Accomplishments
2021 & 2022: Major Accomplishments July 2021: Announced Definitive Agreement to be Listed on Nasdaq through a Business Combination with HealthCor Catalio Acquisition Corp. August 2021: Swoop® Demonstrates High Accuracy for Detection of Brain Hemorrhage in Study Published in Nature Communications Sep
Slide 37: © 2022 Hyperfine, Inc. | Confidential and Proprietary 37
© 2022 Hyperfine, Inc. | Confidential and Proprietary 37
Slide 38: Leadership Team
Leadership Team HYPERFINE
Slide 39: Management Team with Proven Track Record of Success
Management Team with Proven Track Record of Success Dave Scott Chief Executive Officer Alok Gupta Chief Financial Officer Dr. Khan Siddiqui Chief Strategy Officer & Chief Medical Officer Tom Teisseyre Chief Product Officer Mark Hughes Chief Operating Officer Scott White Chief Commercial Officer Kyla
Slide 40: Thank You!
Thank You! ce TN yperfine Swoop HYPERFINE [in Nasdaq ins HYPERFINE
Slide 41: Appendix
Appendix HYPERFINE
Slide 42: Brain is the Largest MRI Market with Nearly 25% of MR Procedures
Brain is the Largest MRI Market with Nearly 25% of MR Procedures N = 27.4 Million Procedures MR Procedure Mix, All Sites, by Percent, 2020 Distribution of MR Sites and Procedures, by Site Type, 2020 3,025 1,765 445 1,000 2,930 8.4 1.8 5.0 6.8 5.4 Spine Breast Chest Pelvis & Abdomen (including liver)